The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.
“As of August, we have completed dose levels 1 and 2, in the escalation component of our phase 1 trial. We’ve seen a very pleasant surprise, a partial response in a patient who has stage 4b gastric cancer at the second dose level, which is still a very low dose level. This patient has metastatic disease, and essentially had passed 2 prior treatment lines, including HER2-targeted therapies.”
TAC01-HER2 (Triumvira Immunologics), a HER2-targeted T-cell antigen coupler (TAC) T-cell therapy, was well-tolerated and demonstrated early signs of clinical activity, including a partial response in a patient with stage 4b gastric cancer and a 75% disease control rate in cohort 2.
These data, from the phase 1/2 TACTIC-2 study, were presented at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9-13, in Paris, France, by Benjamin L. Schlechter, MD, instructor, medicine, Harvard Medical School, and Dana-Farber Cancer Institute.
CGTLive spoke with Deyaa Adib, MD, chief medical officer, Triumvira Immunologics, and senior author of the poster to learn more about the study and its recent updates. He discussed the trial’s progress so far and the cases of stable disease and partial response. The trial will be enrolling in its phase 2 portion in the beginning of 2023.